Plasma Ceramide Species Are Associated with Diabetes Risk in Participants of the Strong Heart Study.

MedStar author(s):
Citation: Journal of Nutrition. 150(5):1214-1222, 2020 05 01.PMID: 31665380Institution: MedStar Health Research InstituteForm of publication: Journal ArticleMedline article type(s): Journal ArticleSubject headings: *Ceramides/bl [Blood] | *Diabetes Mellitus, Type 2/bl [Blood] | *Indians, North American | Adult | Aged | Arizona | Case-Control Studies | Ceramides/ch [Chemistry] | Diabetes Mellitus, Type 2/eh [Ethnology] | Female | Follow-Up Studies | Humans | Male | Middle Aged | North Dakota | Oklahoma | Prospective Studies | Risk Factors | South Dakota | Sphingolipids/bl [Blood] | Sphingomyelins/bl [Blood]Year: 2020Local holdings: Available online from MWHC library: Sept 1928 - present (after 1 year)ISSN:
  • 0022-3166
Name of journal: The Journal of nutritionAbstract: BACKGROUND: Few studies have assessed the associations of ceramides and sphingomyelins (SMs) with diabetes in humans.CONCLUSIONS: Higher concentrations of circulating Cer-18, Cer-20, and Cer-22 were associated with a higher risk of developing diabetes in 2 studies of American-Indian adults. This trial was registered at clinicaltrials.gov as NCT00005134. Copyright (c) The Author(s) 2019.METHODS: The analysis included 435 American-Indian participants from the Strong Heart Study (nested case-control design for analyses; mean age: 57 y; 34% male; median time until diabetes 4.3 y for cases) and 1902 participants from the Strong Heart Family Study (prospective design for analyses; mean age: 37 y; 39% male; median 12.5 y of follow-up). Sphingolipid species were measured using stored plasma samples by sequential LC and MS. Using logistic regression and parametric survival models within studies, and an inverse-variance-weighted meta-analysis across studies, we examined associations of 15 ceramides and SM species with incident diabetes.OBJECTIVE: We assessed associations of 15 circulating ceramides and SM species with incident diabetes in 2 studies.RESULTS: There were 446 cases of incident diabetes across the studies. Higher circulating concentrations of ceramides containing stearic acid (Cer-18), arachidic acid (Cer-20), and behenic acid (Cer-22) were each associated with a higher risk of diabetes. The RRs for incident diabetes per 1 SD of each log ceramide species (muM) were 1.22 (95% CI: 1.09, 1.37) for Cer-18, 1.18 (95% CI: 1.06, 1.31) for Cer-20, and 1.20 (95% CI: 1.08, 1.32) for Cer-22. Although the magnitude of the risk estimates for the association of ceramides containing lignoceric acid (Cer-24) with diabetes was similar to those for Cer-18, Cer-20, and Cer-22 (RR = 1.13; 95% CI: 1.01, 1.26), the association was not statistically significant after correction for multiple testing (P = 0.007). Ceramides carrying palmitic acid (Cer-16), SMs, glucosyl-ceramides, or a lactosyl-ceramide were not associated with diabetes risk.All authors: Fretts AM, Hoofnagle A, Howard BV, Jensen PN, King IB, Lemaitre RN, McKnight B, Siscovick DS, Sitlani C, Sotoodehnia N, Umans J, Yu COriginally published: Journal of Nutrition. 2019 Oct 26Fiscal year: FY2020Digital Object Identifier: Date added to catalog: 2019-11-19
Holdings
Item type Current library Collection Call number Status Date due Barcode
Journal Article MedStar Authors Catalog Article 31665380 Available 31665380

Available online from MWHC library: Sept 1928 - present (after 1 year)

BACKGROUND: Few studies have assessed the associations of ceramides and sphingomyelins (SMs) with diabetes in humans.

CONCLUSIONS: Higher concentrations of circulating Cer-18, Cer-20, and Cer-22 were associated with a higher risk of developing diabetes in 2 studies of American-Indian adults. This trial was registered at clinicaltrials.gov as NCT00005134. Copyright (c) The Author(s) 2019.

METHODS: The analysis included 435 American-Indian participants from the Strong Heart Study (nested case-control design for analyses; mean age: 57 y; 34% male; median time until diabetes 4.3 y for cases) and 1902 participants from the Strong Heart Family Study (prospective design for analyses; mean age: 37 y; 39% male; median 12.5 y of follow-up). Sphingolipid species were measured using stored plasma samples by sequential LC and MS. Using logistic regression and parametric survival models within studies, and an inverse-variance-weighted meta-analysis across studies, we examined associations of 15 ceramides and SM species with incident diabetes.

OBJECTIVE: We assessed associations of 15 circulating ceramides and SM species with incident diabetes in 2 studies.

RESULTS: There were 446 cases of incident diabetes across the studies. Higher circulating concentrations of ceramides containing stearic acid (Cer-18), arachidic acid (Cer-20), and behenic acid (Cer-22) were each associated with a higher risk of diabetes. The RRs for incident diabetes per 1 SD of each log ceramide species (muM) were 1.22 (95% CI: 1.09, 1.37) for Cer-18, 1.18 (95% CI: 1.06, 1.31) for Cer-20, and 1.20 (95% CI: 1.08, 1.32) for Cer-22. Although the magnitude of the risk estimates for the association of ceramides containing lignoceric acid (Cer-24) with diabetes was similar to those for Cer-18, Cer-20, and Cer-22 (RR = 1.13; 95% CI: 1.01, 1.26), the association was not statistically significant after correction for multiple testing (P = 0.007). Ceramides carrying palmitic acid (Cer-16), SMs, glucosyl-ceramides, or a lactosyl-ceramide were not associated with diabetes risk.

English

Powered by Koha